Response on Contrast-Enhanced CT
| Response category | Target lesions | Liver-specific | Abdomen |
| 3 mo | |||
| Complete response | — | — | — |
| Partial response | 5 (14) | 5 (14) | 5 (14) |
| Stable disease | 22 (59) | 13 (35) | 9 (24) |
| Progressive disease* | 10 (27) | 19 (51) | 23 (62) |
| Total | 37 (100) | 37 (100) | 37 (100) |
| 6 mo | |||
| Complete response | 1 (3) | 1 (3) | 1 (3) |
| Partial response | 2 (5) | 2 (5) | 2 (5) |
| Stable disease | 10 (26) | 4 (11) | 3 (8) |
| Progressive disease* | 25 (66) | 31 (82) | 32 (84) |
| Total | 38 (100) | 38 (100) | 38 (100) |
| 9 mo | |||
| Complete response | 1 (3) | 1 (3) | 1 (3) |
| Partial response | 1 (3) | — | — |
| Stable disease | 2 (5) | 1 (3) | 1 (3) |
| Progressive disease* | 34 (89) | 36 (95) | 36 (95) |
| Total | 38 (100) | 38 (100) | 38 (100) |
| 12 mo | |||
| Complete response | — | — | — |
| Partial response | — | — | — |
| Stable disease | 2 (5) | — | — |
| Progressive disease* | 36 (95) | 38 (100) | 38 (100) |
| Total | 38 (100) | 38 (100) | 38 (100) |
↵* Not evaluable, or disease progression was inferred for patients with missing data.
Data are n followed by percentage in parentheses. Timing was at median of 90 d (range, 76–104 d) after treatment at 3 mo, 181 d (152–195) at 6 mo, 278 d (252–312) at 9 mo, and 369 d (368–369) at 12 mo.